德尔塔变异株新型冠状病毒感染危重型病例报告并文献复习

Critical coronavirus disease 2019 caused by Delta variant:a case report with literature review

目的探讨德尔塔变异株新型冠状病毒(新冠病毒)感染康复者恢复期血浆(CP)在治疗重型、危重型患者中的疗效和应用价值。方法报道1例应用CP成功治疗德尔塔变异株新冠病毒感染所致危重型患者的治疗经过及结果,结合文献分析CP治疗德尔塔变异株新冠病毒感染的临床应用价值。结果该例患者为男性,50岁,由境外输入,未接种新冠疫苗,入境前新冠病毒核酸检测阴性。入境后次日出现发热症状,新冠病毒核酸检测阳性,胸部CT检查示双肺多发小片状磨玻璃影,并伴有恶心、头痛、食欲减退、腹泻,无流涕、鼻塞、呼吸困难,无嗅觉和味觉异常,感染后迅速由普通型进展为危重型。在综合救治基础上,于入院第10天(转为重型的第6天)给予输注德尔塔新冠肺炎康复者CP治疗,该例患者的病情快速好转。结论通过对该患者进行疗效评估,认为CP治疗在重型及危重型新冠肺炎患者的治疗方面有重要价值。

Objective To investigate the curative efficacy and application value of convalescent plasma(CP)in severe and critical coronavirus disease 2019(COVID-19)caused by Delta variant.Methods The treatment process and results of CP therapy for a patient with critical COVID-19 caused by Delta variant were reported.The clinical application value of CP for COVID-19 caused by Delta variant was analyzed along with the literature review.Results Our case was a 50-year-old male,who was imported from abroad and had not been vaccinated against COVID-19.The novel coronavirus nucleic acid test was negative before entry.On the second day after entry,fever occurred,novel coronavirus nucleic acid test was positive.Chest CT images showed bilateral multiple mottling and ground-glass opacity with symptoms of nausea,headache,loss of appetite,diarrhea,but no running nose,nasal obstruction,dyspnea,abnormal smell and taste.The infection rapidly developed from medium to critical.On the basis of standard treatment,Delta variant CP was intravenous dripped on the 10th day of hospital admission(the 6th day after becoming severe).The patient's condition improved rapidly.Conclusion The curative efficacy evaluation of this patient proved that CP therapy is of great value in the treatment of severe and critical COVID-19.